Skip to content

Study · Case report or series · n = 1 · 2026

5 results

A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis.

Rallabandi S, Sharma M, Kosuru K, Kashyap R

Cureus27 Feb 2026

PMID41913883 (opens in a new tab)PMCIDPMC13033244 (opens in a new tab)DOI10.7759/cureus.104376 (opens in a new tab)PepBankPUB-41913883
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used in the treatment of diabetes mellitus and obesity. They have proven to be cardioprotective, neuroprotective, and renoprotective, and are now also being considered for drug addiction. There has been increasing demand for these medications over the last several years, with the most common side effects being nausea, vomiting, and constipation. Nausea and vomiting are known to improve over a period of time due to tachyphylaxis. We present the case of a 59-year-old Hispanic obese female on semaglutide for weight loss. Her medication dose was recently increased from 0.25 mg to 0. 5mg under her physician's supervision. She presented with nausea, vomiting, and abdominal pain, which was later diagnosed as small bowel obstruction (SBO) from severe ileus, and developed acute kidney injury (AKI) requiring hemodialysis for several weeks. This case was also complicated because of the past medical history of autoimmune disorder and granulomatosis polyangiitis, which required additional testing to rule out a possible autoimmune etiology of the current presentation. To our knowledge, this is a rare case of semaglutide-associated SBO and concomitant AKI requiring temporary dialysis, highlighting the adverse effects of GLP-1 receptor agonists and the need for further studies to help formulate best practice guidelines.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In an obese woman taking semaglutide for weight loss, small bowel obstruction from severe ileus was diagnosed after a dose increase.

    In plain wordsIn one woman taking semaglutide for weight loss, a small bowel obstruction from severe ileus was diagnosed after her dose went up.

    Peptide
    Semaglutide
    Outcome
    IncreaseSmall bowel obstruction from severe ileus
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which was later diagnosed as small bowel obstruction (SBO) from severe ileus
    2 context sentences
    Summary · context
    We present the case of a 59-year-old Hispanic obese female on semaglutide for weight loss.
    Summary · context
    Her medication dose was recently increased from 0.25 mg to 0. 5mg under her physician's supervision.
  2. 02HumanCase report or seriesSafety outcome

    In an obese woman taking semaglutide for weight loss, acute kidney injury developed and needed hemodialysis for several weeks.

    In plain wordsIn one woman taking semaglutide for weight loss, acute kidney injury developed and needed dialysis for several weeks.

    Peptide
    Semaglutide
    Outcome
    IncreaseAcute kidney injury requiring hemodialysis
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    developed acute kidney injury (AKI) requiring hemodialysis for several weeks.
    2 context sentences
    Summary · context
    We present the case of a 59-year-old Hispanic obese female on semaglutide for weight loss.
    Summary · context
    Her medication dose was recently increased from 0.25 mg to 0. 5mg under her physician's supervision.
  3. 03HumanCase report or seriesSafety outcome

    In an obese woman taking semaglutide, nausea was a presenting symptom of small bowel obstruction.

    In plain wordsIn one woman taking semaglutide, nausea was one of the symptoms when she came to hospital.

    Peptide
    Semaglutide
    Outcome
    IncreaseNausea at presentation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    She presented with nausea, vomiting, and abdominal pain
    2 context sentences
    Summary · context
    We present the case of a 59-year-old Hispanic obese female on semaglutide for weight loss.
    Summary · context
    Her medication dose was recently increased from 0.25 mg to 0. 5mg under her physician's supervision.
  4. 04HumanCase report or seriesSafety outcome

    In an obese woman taking semaglutide, vomiting was a presenting symptom of small bowel obstruction.

    In plain wordsIn one woman taking semaglutide, vomiting was one of the symptoms when she came to hospital.

    Peptide
    Semaglutide
    Outcome
    IncreaseVomiting at presentation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    She presented with nausea, vomiting, and abdominal pain
    2 context sentences
    Summary · context
    We present the case of a 59-year-old Hispanic obese female on semaglutide for weight loss.
    Summary · context
    Her medication dose was recently increased from 0.25 mg to 0. 5mg under her physician's supervision.
  5. 05HumanCase report or seriesSafety outcome

    In an obese woman taking semaglutide, abdominal pain was a presenting symptom of small bowel obstruction.

    In plain wordsIn one woman taking semaglutide, abdominal pain was one of the symptoms when she came to hospital.

    Peptide
    Semaglutide
    Outcome
    IncreaseAbdominal pain at presentation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    She presented with nausea, vomiting, and abdominal pain
    2 context sentences
    Summary · context
    We present the case of a 59-year-old Hispanic obese female on semaglutide for weight loss.
    Summary · context
    Her medication dose was recently increased from 0.25 mg to 0. 5mg under her physician's supervision.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.